GZPHF Stock Chart & Stats
$2.34
$0.20(9.35%)
At close: 4:00 PM EST
$2.34
$0.20(9.35%)
Day’s Range― - ―
52-Week Range$1.99 - $2.64
Previous CloseN/A
Volume300.00
Average Volume (3M)0.00
Market Cap
$4.47B
Enterprise Value$24.04K
Total Cash (Recent Filing)$25.66B
Total Debt (Recent Filing)$19.54B
Price to Earnings (P/E)12.5
Beta0.03
Next Earnings
Oct 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield4.71%
Share Statistics
EPS (TTM)1.57
Shares Outstanding219,900,000
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio1.68
Price to Book (P/B)0.68
Price to Sales (P/S)0.33
P/FCF Ratio-27.11
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$2.64Price Target Upside12.79% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.25
Revenue Forecast (FY)$10.01B
Bulls Say, Bears Say
Bulls Say
Diversified Healthcare Business ModelOperations span pharmaceutical research, manufacturing, sales and healthcare-related distribution, creating multiple channels for scale and reducing reliance on a single product or activity over the medium term.
Moderate Leverage And Growing EquityModerate leverage and a steadily expanding equity base provide financial flexibility to support operations and investment, while reducing the risk that debt materially constrains the company during a weaker earnings period.
Positive Operating Cash Flow And Free Cash FlowThe latest twelve-month period generated meaningful operating and free cash flow, demonstrating that the business can still convert operations into cash and fund needs internally despite recent volatility in cash generation.
Bears Say
Sharp Recent Revenue SlowdownThe severe decline in the latest revenue run-rate raises questions about demand, product mix or operating continuity. Sustained weakness would limit scale benefits and make recovery in profitability more difficult.
Margin And Return-on-equity CompressionLower margins and ROE indicate weaker earnings efficiency than in prior periods. If the compression persists, the company may have less capacity to reinvest, reward shareholders or absorb cost and pricing pressures.
Uneven Cash ConversionCash generation has been volatile and latest free cash flow remains well below accounting earnings. Working-capital or investment demands could therefore reduce funds available for debt service, reinvestment and distributions.
Guangzhou Baiyunshan Pharmaceutical Holdings Company News
GZPHF FAQ
What was Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H’s price range in the past 12 months?
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H lowest stock price was $1.99 and its highest was $2.64 in the past 12 months.
What is Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H’s market cap?
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H’s market cap is $4.47B.
When is Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H’s upcoming earnings report date?
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H’s upcoming earnings report date is Oct 27, 2026 which is in 35 days.
How were Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H’s earnings last quarter?
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H released its earnings results on Aug 21, 2026. The company reported $0.193 earnings per share for the quarter.
Is Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H overvalued?
According to Wall Street analysts Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H’s price is currently Undervalued.
Does Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H pay dividends?
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H pays a Semiannually dividend of $0.044 which represents an annual dividend yield of 4.71%. See more information on Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H dividends here
What is Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H’s EPS estimate?
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H have?
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H has 219,900,000 shares outstanding.
What happened to Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H’s price movement after its last earnings report?
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H reported an EPS of $0.193 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H?
Currently, no hedge funds are holding shares in GZPHF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Guangzhou Baiyunshan Pharmaceutical Holdings Company Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
4.88%
12-Months-Change
Fundamentals
Return on Equity
4.71%
Trailing 12-Months
Asset Growth
12.52%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (GBPHCL) is a comprehensive pharmaceutical enterprise focused on the research, development, production, and distribution of a wide array of medical products. These offerings span traditional Chinese patent medicines, Western pharmaceuticals, chemical raw materials and their intermediates, alongside natural and biological remedies, serving both the Chinese domestic market and international clientele. The company's operations are strategically divided into four primary segments: Great Southern TCM, Great Commerce, Great Health, and Others. Beyond its manufacturing activities, GBPHCL is actively involved in the import, export, wholesale, and retail of both Western and Chinese medicines, as well as medical equipment. The company also develops, manufactures, and sells various consumer goods including beverages, food products, health supplements, pre-packaged foods, dairy items, and diverse pharmaceutical forms such as tablets, capsules, lozenges, and injections, in addition to traditional items like tortoise herb jelly. Furthermore, GBPHCL makes strategic investments in the broader health industry, covering areas like medical services, health management, wellness initiatives, and elderly care. It also provides commercial and advertising solutions. As of December 31, 2021, the company maintained a substantial retail presence, managing 154 chain pharmacies operating under brands like Cai Zhi Lin, Jian Min, GPC Prescription Pharmacy, and Hainan Guangyao Chenfei Pharmaceutical Chain Co., Ltd, supplemented by an additional 22 independent retail stores. Established in 1997, the company originally operated as Guangzhou Pharmaceutical Company Limited before adopting its current name, Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited, in August 2013. Its headquarters are situated in Guangzhou, China.
Guangzhou Baiyunshan Pharmaceutical Holdings Company (GZPHF) Earnings & Revenues
GZPHF Stock 12 Month Forecast
Average Price Target
$2.64
▲(12.79% Upside)
Technical Analysis
China Medical System Holdings
―
Livzon Pharmaceutical Group
―
Shanghai Fosun Pharmaceutical (Group) Co
―
China Resources Pharmaceutical Group Ltd.
―
Grand Pharmaceutical Group Limited
―
Ownership Overview
―
Insiders
4.52% Mutual Funds
― Other Institutional Investors
91.13% Public Companies and
Individual Investors








